enGene Therapeutics Inc. (ENGN)
Nasdaq · Healthcare · Biotechnology
$1.87−3.61%as of Oct 6, 2026, 4:35 AM ET
- Market cap
- $125M
- 52-week range
- $1.40 – $12.25
- 52-week change
- −74.47%
- EPS (trailing)
- −$2.07
Fiscal year to Oct 2025
- Net income
- −$117M
- Diluted EPS
- $2.29
- Free cash flow
- −$101M
From the company’s annual report on SEC EDGAR.
About enGene Therapeutics Inc.
enGene Therapeutics Inc., through its subsidiary enGene, Inc., operates as a clinical-stage biotechnology company in Canada. The company develops genetic medicines to help patients suffering from bladder cancer. Its lead product candidate is detalimogene voraplasmid, a monotherapy for the treatment of non-muscle invasive bladder cancer (NMIBC). Its pipeline includes LEGEND, which is in Phase 2. The company was formerly known as enGene Holdings Inc. and changed its name to enGene Therapeutics Inc. in April 2026. enGene Therapeutics Inc. is based in Montreal, Canada.
Headquarters: Montreal, Canada · 81 employees · engene.com